ClinicalTrials.gg
CompletedNCT07134127Updated Nov 17, 2025

A Study of IBI3032 in Chinese Healthy Subjects

An Early Phase 1 interventional study of placebo and IBI3032 in Healthy, sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center). Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center) (part of Innovent Biologics, Inc.) · Early Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled Phase I clinical study evaluating the safety, tolerability, PK and food effect of a single dose of IBI3032 in healthy participants. This is a single ascending dose (SAD) study. Approximately 40 healthy participants are expected to be enrolled in this study. The screening period is 4 weeks. Eligible participants will be divided into 4 cohorts. Cohort1,2,4 consisted of 8 healthy participants who will be randomized in a 6:2 ratio to receive a single dose of IBI3032 or placebo. The safety follow-up period is 15 days. Cohort 3 consisted of 16 participants used a two-cycle, double-crossover design, who were randomly divided into four groups at a ratio of 3:1:3:1: Cohort 3-1-IBI3032, cohort 3-1-placebo, cohort 3-2-IBI3032, and cohort 3-2-placebo, each subject underwent two cycles of the trial. In cohort 3-1, the first cycle was given on fasted administration, and the second cycle was given after breakfast. In cohort 3-2, the first cycle was administered after breakfast intake, and the second cycle was administered fasted. The washout period for cohort 3-1 and cohort 3-2 was 8 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Innovent Biologics Technology Limited (Shanghai R&D Center) is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or females, as determined by medical history
  • Have safety laboratory results within normal reference ranges

Exclusion criteria

Exclusion Criteria:

  • Have known allergies toIBI3032, glucagon-like peptide-1 (GLP-1) analogs, related compounds
  • Abnormal (ECG) at screening
  • Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Single dose1 of IBI3032 administered orally.

    dose1 IBI3032

    Drug: IBI3032

  • Placebo comparator
    Single dose4 of placebo administered orally.

    dose4 placebo

    Drug: placebo

  • Experimental
    Single dose4 of IBI3032 administered orally.

    dose4 IBI3032

    Drug: IBI3032

  • Active comparator
    D1:Single dose3-1 of placebo administered orally. D9:Single dose3-1 of placebo administered orally.

    D1: Fasted administer D9:Administer after meal

    Drug: placebo

  • Experimental
    Single dose2 of IBI3032 administered orally.

    dose2 IBI3032

    Drug: IBI3032

  • Active comparator
    D1:Single dose3-2 of placebo administered orally. D9:Single dose3-2 of placebo administered orally.

    D1:Administer after meal D9: Fasted administer

    Drug: placebo

  • Experimental
    D1:Single dose3-2 of IBI3032 administered orally. D9:Single dose3-2 of IBI3032 administered orally.

    D1:Administer after meal D9: Fasted administer

    Drug: IBI3032

  • Experimental
    D1:Single dose3-1 of IBI3032 administered orally. D9:Single dose3-1 of IBI3032 administered orally.

    D1: Fasted administer D9:Administer after meal

    Drug: IBI3032

  • Placebo comparator
    Single dose1 of placebo administered orally.

    dose1 placebo

    Drug: placebo

  • Placebo comparator
    Single dose2 of placebo administered orally.

    dose2 placebo

    Drug: placebo

Interventions

  • Drugplacebo

    Placebo (without active ingredients) (cohort1, 2,4) Method of administration: oral, fasted administration. Placebo (without active ingredients) (cohort3) Method of administration: oral, administration after meal.

  • IBI3032: (cohort1, 2,4) Method of administration: oral, fasted administration. IBI3032: (cohort3) Method of administration: oral, administration after meal.

06

What researchers measure

Primary outcomes

  1. Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: (Cohoet1,2,4) Baseline up to Day 15 (Cohoet3) Baseline up to Day 15

  2. Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug

    A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: (Cohoet1,2,4) Baseline up to Day 15 (Cohoet3) Baseline up to Day 15

  3. Number of Participants with adverse events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

    Time frame: (Cohoet1,2,4) Baseline up to Day 15 (Cohoet3) Baseline up to Day 15

Secondary outcomes

  1. Under the Serum Concentration-time Curve (AUC) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

  2. maximum concentration (Cmax) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

  3. time to maximum concentration (Tmax) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

  4. clearance (CL) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

  5. apparent volume of distribution (V) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

  6. elimination half-life (T1/2) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

07

Study locations

1 site
  • The Frist Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Oct 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartActual
Aug 29, 2025
Primary completionActual
Oct 7, 2025
CompletionActual
Oct 7, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07134127
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Aug 29, 2025
Primary completion
Oct 7, 2025
Completion
Oct 7, 2025
Last update
Nov 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI3032

Start the discussion